Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03036930 · ClinicalTrials.gov registry record · Phase 2

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

A Phase 2 study of Human Papillomavirus Infection and Human Papillomavirus-Related Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
51
Enrollment target
6
Study locations

NCT03036930 is a Phase 2 study of Human Papillomavirus Infection and Human Papillomavirus-Related Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 51 participants, below the 1,316-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03036930, a Phase 2 study of Human Papillomavirus Infection and Human Papillomavirus-Related Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
51 participants
Enrollment target
6
Study locations

Study Summary

This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period when they receive immunosuppressive drugs to prevent transplant rejection. This study will help inform our scientific understanding about vaccine-induced immune responses among immunosuppressed individuals.

Interventions

  • PROCEDURE Biospecimen Collection
  • OTHER Questionnaire Administration
  • BIOLOGICAL Recombinant Human Papillomavirus Nonavalent Vaccine
  • PROCEDURE HPV Self-Collection

Study Locations (6)

California

  • Cedars Sinai Medical Center - Los Angeles
  • UCSF Medical Center-Mount Zion - San Francisco

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Illinois

  • Northwestern University - Chicago

Minnesota

  • Mayo Clinic in Rochester - Rochester

North Carolina

  • UNC Lineberger Comprehensive Cancer Center - Chapel Hill

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2017-06-23
Est. Completion 2026-03-06
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT03036930

The ClinicalTrials.gov registry entry for NCT03036930 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,316-participant average among 17 other Human Papillomavirus Infection trials with a reported enrollment target (96% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Human Papillomavirus Infection appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.

NCT03036930 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Illinois.

Frequently Asked Questions

What is clinical trial NCT03036930 about?

NCT03036930 is a clinical study titled "Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients". This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period when they receive immunosuppressive drugs to prevent transplant rejectio...

What is the current status of trial NCT03036930?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2017-06-23. Estimated completion is 2026-03-06.

What conditions does trial NCT03036930 study?

This clinical trial studies the following conditions: Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma.

What interventions are being tested in trial NCT03036930?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER), Recombinant Human Papillomavirus Nonavalent Vaccine (BIOLOGICAL), HPV Self-Collection (PROCEDURE).

Who is sponsoring clinical trial NCT03036930?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03036930 being conducted?

This trial has 6 study locations across Alabama, California, Illinois, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Human Papillomavirus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.